Both B-Claim
UAE I-Claim
and I-Claim
hysterectomy I-Claim
improved I-Claim
HRQOL I-Claim
. I-Claim

In B-Claim
endocrine I-Claim
therapy I-Claim
trials I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
patients I-Claim
with I-Claim
response I-Claim
( I-Claim
complete I-Claim
response/partial I-Claim
response I-Claim
[ I-Claim
CR/PR I-Claim
] I-Claim
) I-Claim
and I-Claim
patients I-Claim
with I-Claim
stable I-Claim
disease I-Claim
for I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
( I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
have I-Claim
shown I-Claim
similar I-Claim
survival I-Claim
and I-Claim
therefore I-Claim
are I-Claim
often I-Claim
defined I-Claim
as I-Claim
a I-Claim
population I-Claim
with I-Claim
clinical I-Claim
benefit I-Claim
( I-Claim
patients I-Claim
with I-Claim
CR/PR I-Claim
or I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
. I-Claim

PS B-Claim
and I-Claim
other I-Claim
prognostic I-Claim
factors I-Claim
could I-Claim
influence I-Claim
the I-Claim
response I-Claim
rate I-Claim
, I-Claim
which I-Claim
does I-Claim
not I-Claim
appear I-Claim
to I-Claim
be I-Claim
a I-Claim
reliable I-Claim
parameter I-Claim
for I-Claim
evaluating I-Claim
the I-Claim
outcome I-Claim
of I-Claim
chemotherapy I-Claim
trials I-Claim
. I-Claim

The B-Claim
observation I-Claim
that I-Claim
longer I-Claim
infusion I-Claim
produces I-Claim
more I-Claim
myelosuppression I-Claim
but I-Claim
does I-Claim
not I-Claim
yield I-Claim
higher I-Claim
response I-Claim
rates I-Claim
should I-Claim
lead I-Claim
to I-Claim
further I-Claim
studies I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimal I-Claim
dose I-Claim
and I-Claim
schedule I-Claim
of I-Claim
this I-Claim
interesting I-Claim
new I-Claim
agent I-Claim
. I-Claim

The B-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
for I-Claim
radiation I-Claim
oncology I-Claim
is I-Claim
a I-Claim
useful I-Claim
guide I-Claim
to I-Claim
the I-Claim
level I-Claim
of I-Claim
nutrition I-Claim
support I-Claim
required I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
plus I-Claim
GM-CSF I-Claim
is I-Claim
not I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
strategy I-Claim
when I-Claim
compared I-Claim
with I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
alone I-Claim
. I-Claim

Laser B-Claim
treatment I-Claim
appeared I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
facial I-Claim
hair I-Claim
and I-Claim
time I-Claim
spent I-Claim
on I-Claim
hair I-Claim
removal I-Claim
as I-Claim
well I-Claim
as I-Claim
alleviating I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
in I-Claim
women I-Claim
with I-Claim
PCOS I-Claim
. I-Claim

A B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim

FJD B-Claim
combined I-Claim
chemotherapy I-Claim
could I-Claim
effectively I-Claim
improve I-Claim
the I-Claim
QOL I-Claim
of I-Claim
solid I-Claim
tumor I-Claim
children I-Claim
patients I-Claim
, I-Claim
elevate I-Claim
their I-Claim
survival I-Claim
rate I-Claim
, I-Claim
and I-Claim
prolong I-Claim
their I-Claim
life I-Claim
spans I-Claim
. I-Claim

Patient B-Claim
QOL I-Claim
favours I-Claim
delivering I-Claim
cancer I-Claim
treatment I-Claim
in I-Claim
the I-Claim
home I-Claim
rather I-Claim
than I-Claim
GP I-Claim
surgeries I-Claim
. I-Claim

The B-Claim
two I-Claim
chemotherapy I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
similar I-Claim
effectiveness I-Claim
in I-Claim
symptom I-Claim
palliation I-Claim
when I-Claim
evaluated I-Claim
with I-Claim
C30 I-Claim
addendum I-Claim
of I-Claim
EORTC I-Claim
QOL I-Claim
questionnaire I-Claim
. I-Claim

Two B-Claim
months I-Claim
after I-Claim
starting I-Claim
treatment I-Claim
there I-Claim
were I-Claim
no I-Claim
significant I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
between I-Claim
the I-Claim
arms I-Claim
. I-Claim

Combined B-Claim
cardiorespiratory I-Claim
and I-Claim
resistance I-Claim
training I-Claim
, I-Claim
even I-Claim
of I-Claim
very I-Claim
brief I-Claim
duration I-Claim
, I-Claim
improves I-Claim
the I-Claim
QOL I-Claim
and I-Claim
the I-Claim
overall I-Claim
physical I-Claim
fitness I-Claim
of I-Claim
women I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

To B-Claim
our I-Claim
knowledge I-Claim
, I-Claim
this I-Claim
study I-Claim
provided I-Claim
novel I-Claim
evidence I-Claim
that I-Claim
MBSR I-Claim
can I-Claim
help I-Claim
alleviate I-Claim
long-term I-Claim
emotional I-Claim
and I-Claim
physical I-Claim
adverse I-Claim
effects I-Claim
of I-Claim
medical I-Claim
treatments I-Claim
, I-Claim
including I-Claim
endocrine I-Claim
treatments I-Claim
. I-Claim

In B-Claim
the I-Claim
watchful-waiting I-Claim
group I-Claim
, I-Claim
side-effects I-Claim
can I-Claim
be I-Claim
caused I-Claim
by I-Claim
tumour I-Claim
progression I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
brief I-Claim
pilot I-Claim
counseling I-Claim
intervention I-Claim
demonstrated I-Claim
significant I-Claim
gains I-Claim
in I-Claim
sexual I-Claim
function I-Claim
and I-Claim
satisfaction I-Claim
and I-Claim
increased I-Claim
utilization I-Claim
of I-Claim
treatments I-Claim
for I-Claim
ED I-Claim
. I-Claim

Response B-Claim
proportion I-Claim
and I-Claim
survival I-Claim
did I-Claim
not I-Claim
improve I-Claim
significantly I-Claim
with I-Claim
the I-Claim
addition I-Claim
of I-Claim
13-CRA I-Claim
to I-Claim
IFNalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
RCC I-Claim
. I-Claim

Oral B-Claim
Etoposide I-Claim
therapy I-Claim
resulted I-Claim
in I-Claim
better I-Claim
total I-Claim
FLI-C I-Claim
QOL I-Claim
score I-Claim
than I-Claim
radiotherapy I-Claim
. I-Claim

Acupuncture B-Claim
is I-Claim
an I-Claim
effective I-Claim
intervention I-Claim
for I-Claim
managing I-Claim
the I-Claim
symptom I-Claim
of I-Claim
CRF I-Claim
and I-Claim
improving I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Overall B-Claim
survival I-Claim
was I-Claim
not I-Claim
statistically I-Claim
significantly I-Claim
improved I-Claim
at I-Claim
this I-Claim
time I-Claim
. I-Claim

The B-Claim
clinical I-Claim
efficacy I-Claim
of I-Claim
pemetrexed I-Claim
and I-Claim
gemcitabine I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
previously I-Claim
untreated I-Claim
advanced I-Claim
NSCLC I-Claim
was I-Claim
roughly I-Claim
the I-Claim
same I-Claim
, I-Claim
but B-Claim
the I-Claim
adverse I-Claim
reactions I-Claim
decreased I-Claim
significantly I-Claim
in I-Claim
the I-Claim
PP I-Claim
group I-Claim
compared I-Claim
with I-Claim
those I-Claim
in I-Claim
the I-Claim
GP I-Claim
group I-Claim
. I-Claim

However B-Claim
, I-Claim
identification I-Claim
of I-Claim
prognostic I-Claim
factors I-Claim
from I-Claim
responses I-Claim
to I-Claim
questionnaires I-Claim
may I-Claim
be I-Claim
unstable I-Claim
, I-Claim
and I-Claim
their I-Claim
reliability I-Claim
and I-Claim
clinical I-Claim
utility I-Claim
should I-Claim
be I-Claim
tested I-Claim
prospectively I-Claim
. I-Claim

Hypnosis B-Claim
appears I-Claim
to I-Claim
reduce I-Claim
perceived I-Claim
hot I-Claim
flashes I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
may I-Claim
have I-Claim
additional I-Claim
benefits I-Claim
such I-Claim
as I-Claim
reduced I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
, I-Claim
and I-Claim
improved I-Claim
sleep I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
of I-Claim
DPPE I-Claim
are I-Claim
warranted I-Claim
. I-Claim

Hot B-Claim
flash I-Claim
frequency I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
was I-Claim
reduced I-Claim
following I-Claim
acupuncture I-Claim
. I-Claim

Although B-Claim
these I-Claim
findings I-Claim
are I-Claim
promising I-Claim
, I-Claim
a I-Claim
larger I-Claim
study I-Claim
is I-Claim
needed I-Claim
to I-Claim
determine I-Claim
more I-Claim
specifically I-Claim
what I-Claim
short- I-Claim
and I-Claim
long-term I-Claim
effects I-Claim
are I-Claim
possible I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
this I-Claim
first I-Claim
randomized I-Claim
study I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
any I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
using I-Claim
estramustine I-Claim
in I-Claim
addition I-Claim
to I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
however B-Claim
, I-Claim
a I-Claim
trend I-Claim
for I-Claim
a I-Claim
positive I-Claim
response I-Claim
for I-Claim
the I-Claim
estramustine I-Claim
group I-Claim
was I-Claim
found I-Claim
in I-Claim
patients I-Claim
with I-Claim
grade I-Claim
III I-Claim
glioma I-Claim
. I-Claim

The B-Claim
behaviorally I-Claim
oriented I-Claim
intervention I-Claim
brought I-Claim
about I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
indicated I-Claim
a I-Claim
trend I-Claim
toward I-Claim
improved I-Claim
CRF I-Claim
, I-Claim
but I-Claim
detected I-Claim
no I-Claim
effect I-Claim
for I-Claim
fatigue-related I-Claim
distress I-Claim
. I-Claim

Both B-Premise
treatments I-Premise
led I-Premise
to I-Premise
an I-Premise
improvement I-Premise
, I-Premise
over I-Premise
time I-Premise
, I-Premise
in I-Premise
dyspnoea I-Premise
. I-Premise

The B-Premise
16-week I-Premise
regimen I-Premise
produced I-Premise
marginally I-Premise
better I-Premise
breast I-Premise
cancer I-Premise
outcomes I-Premise
than I-Premise
CAF I-Premise
with I-Premise
similar I-Premise
toxicity I-Premise
but I-Premise
a I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
during-treatment I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

At B-Premise
postintervention I-Premise
, I-Premise
AET I-Premise
was I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
patient-rated I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
group I-Premise
difference I-Premise
, I-Premise
+9.0 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.0 I-Premise
to I-Premise
16.0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
, I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
, I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
fitness I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
lean I-Premise
body I-Premise
mass I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

Arm B-Premise
volume I-Premise
measured I-Premise
by I-Premise
water I-Premise
displacement I-Premise
was I-Premise
correlated I-Premise
with I-Premise
calculated I-Premise
arm I-Premise
volume I-Premise
( I-Premise
r I-Premise
=.973 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
although B-Premise
the I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
means I-Premise
were I-Premise
significantly I-Premise
different I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
-5 I-Premise
versus I-Premise
3-day I-Premise
comparison I-Premise
, I-Premise
the I-Premise
projected I-Premise
2-year I-Premise
PFS I-Premise
is I-Premise
88.8 I-Premise
% I-Premise
and I-Premise
89.7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
difference I-Premise
, I-Premise
-0.9 I-Premise
% I-Premise
, I-Premise
( I-Premise
80 I-Premise
% I-Premise
CL I-Premise
, I-Premise
-4.1 I-Premise
% I-Premise
, I-Premise
+2.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
18.2 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
18.5 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
0.97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.85 I-Premise
to I-Premise
1.10 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.688 I-Premise
) I-Premise
. I-Premise

HDCT B-Premise
was I-Premise
associated I-Premise
with I-Premise
significantly I-Premise
more I-Premise
myelosuppression I-Premise
, I-Premise
infection I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
treated I-Premise
with I-Premise
AT I-Premise
developed I-Premise
more I-Premise
neurotoxicity I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
significantly I-Premise
better I-Premise
with I-Premise
topotecan I-Premise
compared I-Premise
with I-Premise
observation I-Premise
( I-Premise
3.6 I-Premise
months I-Premise
v I-Premise
2.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Fifty-nine B-Premise
percent I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
duloxetine I-Premise
vs I-Premise
38 I-Premise
% I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
placebo I-Premise
reported I-Premise
decreased I-Premise
pain I-Premise
of I-Premise
any I-Premise
amount I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
13.8 I-Premise
months I-Premise
for I-Premise
arm I-Premise
1 I-Premise
versus I-Premise
14.4 I-Premise
months I-Premise
for I-Premise
arm I-Premise
2 I-Premise
( I-Premise
P I-Premise
=.4 I-Premise
) I-Premise
. I-Premise

No B-Premise
treatment-related I-Premise
death I-Premise
was I-Premise
observed I-Premise
. I-Premise

The B-Premise
KPS I-Premise
score I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
after I-Premise
treatment I-Premise
was I-Premise
improved I-Premise
in I-Premise
13 I-Premise
patients I-Premise
( I-Premise
23.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
27 I-Premise
( I-Premise
49.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
15 I-Premise
( I-Premise
27.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
it I-Premise
was I-Premise
improved I-Premise
in I-Premise
7 I-Premise
( I-Premise
13.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
21 I-Premise
( I-Premise
39.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
25 I-Premise
( I-Premise
47.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
the I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Tamoxifen B-Premise
administration I-Premise
did I-Premise
not I-Premise
alter I-Premise
the I-Premise
average I-Premise
annual I-Premise
rate I-Premise
of I-Premise
ischemic I-Premise
heart I-Premise
disease I-Premise
";" I-Premise
however I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
hip I-Premise
, I-Premise
radius I-Premise
( I-Premise
Colles I-Premise
' I-Premise
) I-Premise
, I-Premise
and I-Premise
spine I-Premise
fractures I-Premise
was I-Premise
observed I-Premise
. I-Premise

The B-Premise
median I-Premise
failure I-Premise
free I-Premise
survival I-Premise
was I-Premise
7.9 I-Premise
months I-Premise
in I-Premise
PVI I-Premise
5-FU I-Premise
plus I-Premise
MMC I-Premise
and I-Premise
5.4 I-Premise
months I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.033 I-Premise
) I-Premise
and I-Premise
at I-Premise
one I-Premise
year I-Premise
31.9 I-Premise
% I-Premise
for I-Premise
the I-Premise
combination I-Premise
compared I-Premise
to I-Premise
17.7 I-Premise
% I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
. I-Premise

Overall B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
events I-Premise
( I-Premise
AEs I-Premise
) I-Premise
was I-Premise
comparable I-Premise
between I-Premise
the I-Premise
ASA404 I-Premise
and I-Premise
placebo I-Premise
arms I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
failure-free I-Premise
survival I-Premise
, I-Premise
time I-Premise
to I-Premise
locoregional I-Premise
failure I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
as I-Premise
measured I-Premise
by I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
and I-Premise
Neck I-Premise
. I-Premise

No B-Premise
decrease I-Premise
in I-Premise
fatigue-related I-Premise
distress I-Premise
was I-Premise
detected I-Premise
. I-Premise

Significantly B-Premise
greater I-Premise
improvements I-Premise
for I-Premise
IMCP I-Premise
patients I-Premise
were I-Premise
also I-Premise
observed I-Premise
for I-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
of I-Premise
symptom I-Premise
burden I-Premise
( I-Premise
b I-Premise
= I-Premise
-6.56 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
symptom-related I-Premise
distress I-Premise
( I-Premise
b I-Premise
= I-Premise
-0.47 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but I-Premise
not I-Premise
for I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
hopelessness I-Premise
. I-Premise

Postoperative B-Premise
morbidity I-Premise
rate I-Premise
was I-Premise
28.9 I-Premise
percent I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
vs. I-Premise
40 I-Premise
percent I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.18 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
between I-Premise
the I-Premise
5-FU+low-dose I-Premise
CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
5-FU I-Premise
arm I-Premise
( I-Premise
479 I-Premise
and I-Premise
491 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

These B-Premise
results I-Premise
show I-Premise
an I-Premise
improvement I-Premise
over I-Premise
previous I-Premise
SIOP I-Premise
study I-Premise
( I-Premise
RMS75 I-Premise
) I-Premise
in I-Premise
which I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
and I-Premise
event-free I-Premise
survival I-Premise
was I-Premise
47 I-Premise
% I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
in I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
induction I-Premise
chemotherapy I-Premise
only I-Premise
was I-Premise
8.9 I-Premise
months I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
( I-Premise
P I-Premise
=.04 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual-care I-Premise
group I-Premise
. I-Premise

Anxiety B-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
SPCG-4 I-Premise
groups I-Premise
( I-Premise
77 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
178 I-Premise
and I-Premise
69 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
161 I-Premise
men I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
68 I-Premise
[ I-Premise
33 I-Premise
% I-Premise
] I-Premise
of I-Premise
208 I-Premise
men I-Premise
";" I-Premise
relative I-Premise
risk I-Premise
1·42 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1·07-1·88 I-Premise
) I-Premise
. I-Premise

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
HRQoL I-Premise
between I-Premise
nurse-led I-Premise
telephone I-Premise
and I-Premise
hospital I-Premise
follow-up I-Premise
at I-Premise
12 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
for I-Premise
difference I-Premise
: I-Premise
-1.93-4.64 I-Premise
) I-Premise
and I-Premise
neither I-Premise
between I-Premise
follow-up I-Premise
with I-Premise
or I-Premise
without I-Premise
EGP I-Premise
( I-Premise
p I-Premise
= I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
for I-Premise
difference I-Premise
: I-Premise
-3.59-3.00 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
in-hospital I-Premise
mortality I-Premise
or I-Premise
early I-Premise
complication I-Premise
rates I-Premise
, I-Premise
but B-Premise
late I-Premise
complications I-Premise
were I-Premise
more I-Premise
frequent I-Premise
after I-Premise
rigid I-Premise
stenting I-Premise
( I-Premise
risk I-Premise
ratio=2.47 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1.88-3.04 I-Premise
) I-Premise
. I-Premise

Of B-Premise
the I-Premise
41 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
swelling I-Premise
at I-Premise
baseline I-Premise
, I-Premise
38 I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

Patients B-Premise
with I-Premise
an I-Premise
objective I-Premise
tumor I-Premise
response I-Premise
reported I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
functional I-Premise
performance I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
less I-Premise
effort I-Premise
to I-Premise
cope I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
non-responders I-Premise
and I-Premise
stable I-Premise
disease I-Premise
patients I-Premise
. I-Premise

The B-Premise
rates I-Premise
of I-Premise
stroke I-Premise
, I-Premise
pulmonary I-Premise
embolism I-Premise
, I-Premise
and I-Premise
deep-vein I-Premise
thrombosis I-Premise
were I-Premise
elevated I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
these I-Premise
events I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise

For B-Premise
response I-Premise
, I-Premise
age I-Premise
, I-Premise
dyspnoea I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
global I-Premise
QL I-Premise
were I-Premise
significant I-Premise
predictive I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal-related I-Premise
event I-Premise
in I-Premise
patients I-Premise
who I-Premise
had I-Premise
such I-Premise
an I-Premise
event I-Premise
was I-Premise
9·2 I-Premise
months I-Premise
( I-Premise
8·1-10·7 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
10·2 I-Premise
months I-Premise
( I-Premise
7·3-14·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
p=0·63 I-Premise
) I-Premise
. I-Premise

No B-Premise
QOL I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
arms I-Premise
. I-Premise

Unmarried B-Premise
, I-Premise
younger I-Premise
patients I-Premise
who I-Premise
were I-Premise
receiving I-Premise
nontaxane-based I-Premise
therapies I-Premise
and I-Premise
had I-Premise
more I-Premise
advanced I-Premise
disease I-Premise
stage I-Premise
experienced I-Premise
better I-Premise
outcomes I-Premise
. I-Premise

In B-Premise
addition I-Premise
, I-Premise
on I-Premise
the I-Premise
physical I-Premise
and I-Premise
psychological I-Premise
subscales I-Premise
, I-Premise
the I-Premise
Etoposide I-Premise
group I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
QOL I-Premise
than I-Premise
the I-Premise
other I-Premise
3 I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

HRQOL B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
were I-Premise
rash I-Premise
, I-Premise
diarrhea I-Premise
and I-Premise
pruritus I-Premise
. I-Premise

Severe B-Premise
rash I-Premise
occurred I-Premise
in I-Premise
9 I-Premise
% I-Premise
and I-Premise
severe I-Premise
diarrhea I-Premise
in I-Premise
6 I-Premise
% I-Premise
of I-Premise
erlotinib-treated I-Premise
patients I-Premise
and I-Premise
each I-Premise
resulted I-Premise
in I-Premise
study I-Premise
discontinuation I-Premise
in I-Premise
1 I-Premise
% I-Premise
of I-Premise
patients I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
for I-Premise
patients I-Premise
with I-Premise
ER-positive I-Premise
tumors I-Premise
, I-Premise
addition I-Premise
of I-Premise
CMF I-Premise
provided I-Premise
no I-Premise
benefit I-Premise
in I-Premise
terms I-Premise
of I-Premise
DFS I-Premise
( I-Premise
5-year I-Premise
DFS I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
85 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
-1 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-6 I-Premise
% I-Premise
to I-Premise
4 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.75 I-Premise
to I-Premise
1.30 I-Premise
";" I-Premise
P I-Premise
=.92 I-Premise
) I-Premise
or I-Premise
OS I-Premise
( I-Premise
5-year I-Premise
OS I-Premise
= I-Premise
95 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
93 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
2 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1 I-Premise
% I-Premise
to I-Premise
5 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.95 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.64 I-Premise
to I-Premise
1.40 I-Premise
";" I-Premise
P I-Premise
=.80 I-Premise
) I-Premise
. I-Premise

Pretreatment B-Premise
serum I-Premise
erythropoietin I-Premise
levels I-Premise
were I-Premise
lower I-Premise
in I-Premise
responders I-Premise
than I-Premise
in I-Premise
nonresponders I-Premise
( I-Premise
73.5 I-Premise
IU/L I-Premise
and I-Premise
86.3 I-Premise
IU/L I-Premise
means I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
changes I-Premise
of I-Premise
BMD I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
patients I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
p=0.011 I-Premise
, I-Premise
CI=0.063-0.437 I-Premise
) I-Premise
, I-Premise
and I-Premise
group I-Premise
C I-Premise
( I-Premise
p=0.003 I-Premise
, I-Premise
CI=0.146-0.620 I-Premise
) I-Premise
. I-Premise

Manual B-Premise
lymphatic I-Premise
drainage I-Premise
showed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
outcomes I-Premise
. I-Premise

Median B-Premise
relative I-Premise
dose I-Premise
intensity I-Premise
over I-Premise
eight I-Premise
cycles I-Premise
( I-Premise
DI8 I-Premise
) I-Premise
was I-Premise
78 I-Premise
% I-Premise
for I-Premise
CPT-11 I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5-FU I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
death I-Premise
number I-Premise
decreased I-Premise
, I-Premise
the I-Premise
survival I-Premise
rate I-Premise
increased I-Premise
, I-Premise
the I-Premise
life I-Premise
span I-Premise
of I-Premise
dead I-Premise
children I-Premise
was I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
showing I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Within B-Premise
the I-Premise
randomised I-Premise
controlled I-Premise
trial I-Premise
, I-Premise
the I-Premise
Barthel I-Premise
Index I-Premise
demonstrated I-Premise
a I-Premise
small I-Premise
but I-Premise
significant I-Premise
fall I-Premise
in I-Premise
functionality I-Premise
with I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
the I-Premise
no I-Premise
radiotherapy I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
SF-8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

The B-Premise
-1 I-Premise
, I-Premise
-2 I-Premise
, I-Premise
and I-Premise
3-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
88.9 I-Premise
% I-Premise
, I-Premise
44.4 I-Premise
% I-Premise
, I-Premise
and I-Premise
16.7 I-Premise
% I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
75.0 I-Premise
% I-Premise
, I-Premise
18.8 I-Premise
% I-Premise
, I-Premise
and I-Premise
0 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
0.299 I-Premise
, I-Premise
0.0035 I-Premise
, I-Premise
0.0014 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

On B-Premise
the I-Premise
response I-Premise
analysis I-Premise
, I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
the I-Premise
bodily I-Premise
pain I-Premise
domain I-Premise
( I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
reporting I-Premise
a I-Premise
worsening I-Premise
of I-Premise
QOL I-Premise
, I-Premise
47 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
51 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
the I-Premise
vasomotor I-Premise
domain I-Premise
( I-Premise
22 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
29 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
level I-Premise
of I-Premise
postoperative I-Premise
satisfaction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
EOF I-Premise
group I-Premise
( I-Premise
82.8 I-Premise
vs. I-Premise
71.7 I-Premise
mm I-Premise
, I-Premise
P I-Premise
B I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
34 I-Premise
and I-Premise
33.7 I-Premise
months I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.68 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
5-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
and I-Premise
51 I-Premise
% I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.94 I-Premise
) I-Premise
. I-Premise

A B-Premise
second I-Premise
infusion I-Premise
of I-Premise
pamidronate I-Premise
did I-Premise
not I-Premise
decrease I-Premise
resorption I-Premise
further I-Premise
, I-Premise
but B-Premise
maintained I-Premise
the I-Premise
suppression I-Premise
of I-Premise
resorption I-Premise
at I-Premise
similar I-Premise
levels I-Premise
for I-Premise
a I-Premise
further I-Premise
four I-Premise
weeks I-Premise
. I-Premise

Neither B-Premise
surgery I-Premise
nor I-Premise
definitive I-Premise
CRT I-Premise
significantly I-Premise
impaired I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
of I-Premise
patients I-Premise
. I-Premise

Analysis B-Premise
of I-Premise
the I-Premise
trial I-Premise
group I-Premise
demonstrated I-Premise
a I-Premise
significant I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
in I-Premise
body I-Premise
weight I-Premise
( I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
fatigue I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Reported B-Premise
adverse I-Premise
events I-Premise
were I-Premise
similar I-Premise
between I-Premise
groups I-Premise
. I-Premise

From B-Premise
cycle I-Premise
5 I-Premise
onwards I-Premise
, I-Premise
improvements I-Premise
relative I-Premise
to I-Premise
baseline/MP I-Premise
were I-Premise
observed I-Premise
for I-Premise
all I-Premise
domains I-Premise
with I-Premise
VMP I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
favor I-Premise
of I-Premise
PPT I-Premise
were I-Premise
also I-Premise
found I-Premise
for I-Premise
the I-Premise
following I-Premise
secondary I-Premise
outcomes I-Premise
: I-Premise
fatigue I-Premise
dimensions I-Premise
" I-Premise
reduced I-Premise
activity I-Premise
" I-Premise
and I-Premise
" I-Premise
reduced I-Premise
motivation I-Premise
, I-Premise
" I-Premise
fatigue I-Premise
NRS I-Premise
, I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
interference I-Premise
of I-Premise
fatigue I-Premise
with I-Premise
daily I-Premise
life I-Premise
, I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
all I-Premise
P I-Premise
≤ I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
on I-Premise
DPPE/DOX I-Premise
arm I-Premise
were I-Premise
significantly I-Premise
worse I-Premise
in I-Premise
terms I-Premise
of I-Premise
average I-Premise
and I-Premise
median I-Premise
pain I-Premise
change I-Premise
scores I-Premise
. I-Premise

The B-Premise
dyspnoea I-Premise
palliation I-Premise
rate I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
C3 I-Premise
arm I-Premise
at I-Premise
18 I-Premise
and I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
finding I-Premise
was I-Premise
inconsistent I-Premise
across I-Premise
different I-Premise
methods I-Premise
of I-Premise
analysis I-Premise
. I-Premise

The B-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
subscale I-Premise
was I-Premise
associated I-Premise
with I-Premise
all I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
( I-Premise
r=-0.45 I-Premise
to I-Premise
-0.70 I-Premise
, I-Premise
all I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
diarrhea I-Premise
occurred I-Premise
in I-Premise
36 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
in I-Premise
19 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

All B-Premise
95 I-Premise
% I-Premise
confidence I-Premise
intervals I-Premise
for I-Premise
the I-Premise
differences I-Premise
were I-Premise
within I-Premise
±10 I-Premise
percentage I-Premise
points I-Premise
, I-Premise
indicating I-Premise
noninferiority I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
EXE I-Premise
( I-Premise
median I-Premise
not I-Premise
reached I-Premise
) I-Premise
than I-Premise
with I-Premise
MA I-Premise
( I-Premise
123.4 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.039 I-Premise
) I-Premise
, I-Premise
as I-Premise
were I-Premise
the I-Premise
median I-Premise
duration I-Premise
of I-Premise
overall I-Premise
success I-Premise
( I-Premise
OR I-Premise
or I-Premise
stable I-Premise
disease I-Premise
> I-Premise
or I-Premise
= I-Premise
24 I-Premise
weeks I-Premise
";" I-Premise
60.1 I-Premise
v I-Premise
49.1 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.025 I-Premise
) I-Premise
, I-Premise
time I-Premise
to I-Premise
tumor I-Premise
progression I-Premise
( I-Premise
20.3 I-Premise
v I-Premise
16.6 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.037 I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
16.3 I-Premise
v I-Premise
15.7 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.042 I-Premise
) I-Premise
. I-Premise

Adjusted B-Premise
linear I-Premise
mixed-model I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
, I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
RET I-Premise
group I-Premise
reported I-Premise
higher I-Premise
self-esteem I-Premise
[ I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.6 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
) I-Premise
, I-Premise
0.1-3.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.032 I-Premise
] I-Premise
and I-Premise
the I-Premise
AET I-Premise
group I-Premise
reported I-Premise
lower I-Premise
anxiety I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
-4.7 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.0 I-Premise
to I-Premise
-9.3 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
of I-Premise
the I-Premise
same I-Premise
period I-Premise
, I-Premise
the I-Premise
2-and I-Premise
3-year I-Premise
somatic I-Premise
functions I-Premise
, I-Premise
psychological I-Premise
functions I-Premise
, I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
2-year I-Premise
somatic I-Premise
functions I-Premise
and I-Premise
psychological I-Premise
functions I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
3-year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
all I-Premise
with I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

For B-Premise
in-hospital I-Premise
mortality I-Premise
, I-Premise
one I-Premise
patient I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
died I-Premise
from I-Premise
anastomotic I-Premise
leakage I-Premise
and I-Premise
two I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
from I-Premise
aspiration I-Premise
and I-Premise
mediastinitis I-Premise
after I-Premise
anastomotic I-Premise
leakage I-Premise
. I-Premise

This O
study O
examined O
factors O
associated O
with O
attrition O
from O
a O
randomized O
controlled O
trial O
comparing O
meaning-centered O
group O
psychotherapy O
( O
MCGP O
) O
, O
an O
intervention O
designed O
to O
help O
advanced O
cancer O
patients O
sustain O
or O
enhance O
their O
sense O
of O
meaning O
to O
the O
supportive O
group O
psychotherapy O
( O
SGP O
) O
, O
a O
standardized O
support O
group O
. O

The O
treatment O
cycle O
was O
once O
every O
three O
weeks O
. O

Approximately O
30 O
% O
of O
lung O
cancer O
cases O
are O
diagnosed O
in O
patients O
> O
70 O
years O
of O
age O
. O

Psychosocial O
symptoms O
were O
assessed O
with O
the O
use O
of O
a O
self-report O
screening O
instrument O
, O
and O
distressed O
women O
were O
referred O
for O
counseling O
if O
needed O
. O

Categorical O
data O
were O
compared O
using O
a O
stratified O
Cochran-Mantel-Haenszel O
test O
. O

Two O
hundred O
fourteen O
patients O
from O
nineteen O
Italian O
centers O
were O
randomized O
to O
the O
control O
arm O
consisting O
of O
biweekly O
cycles O
of O
MTX O
, O
200 O
mg/m2 O
on O
day O
1 O
, O
followed O
by O
bolus O
5-FU O
600 O
mg/m2 O
on O
day O
2 O
and O
6-S-leucovorin O
rescue O
, O
or O
to O
the O
experimental O
arm O
consisting O
of O
two O
biweekly O
cycles O
of O
the O
same O
regimen O
as O
in O
the O
control O
arm O
alternated O
to O
three O
weeks O
of O
continuous O
infusion O
5-FU O
( O
200 O
mg/m2 O
day O
) O
+ O
weekly O
bolus O
6-S-leucovorin O
, O
20 O
mg/m2 O
. O

We O
randomly O
assigned O
56 O
patients O
to O
the O
open O
oesophagectomy O
group O
and O
59 O
to O
the O
minimally O
invasive O
oesophagectomy O
group O
. O

bolus O
( O
arm O
C O
) O
. O

We O
evaluated O
HRQOL O
with O
the O
EuroQol O
( O
EQ-5D™ O
) O
in O
patients O
with O
APC O
participating O
in O
Cancer O
and O
Leukemia O
Group O
B O
80303 O
, O
a O
multicenter O
, O
double-blind O
, O
randomized O
trial O
comparing O
overall O
survival O
( O
OS O
) O
between O
two O
treatment O
arms O
: O
gemcitabine O
with O
bevacizumab O
or O
gemcitabine O
with O
placebo O
. O

Patients O
with O
incompletely O
resected O
tumour O
received O
six O
to O
10 O
courses O
of O
IVA O
according O
to O
stage O
. O

We O
conducted O
a O
prospective O
, O
multicenter O
, O
randomized O
, O
controlled O
, O
clinical O
trial O
with O
215 O
patients O
followed O
until O
death O
or O
study O
closure O
. O

Of O
407 O
patients O
randomized O
, O
391 O
were O
eligible O
and O
382 O
assessable O
for O
response O
. O

Pain O
is O
1 O
of O
the O
most O
common O
symptoms O
that O
a O
cancer O
patient O
would O
experience O
. O

Quality O
of O
life O
assessments O
were O
performed O
using O
the O
EORTC O
QLQ-C30 O
and O
QLQ-OES24 O
modules O
. O

After O
the O
administration O
of O
the O
131-I O
dose O
, O
the O
rate O
of O
radiation O
clearance O
from O
blood O
, O
thyroid O
remnant O
, O
and O
whole O
body O
was O
measured O
. O

A O
total O
of O
166 O
eligible O
patients O
were O
randomly O
assigned O
to O
receive O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
. O

These O
differences O
all O
resolved O
by O
12 O
months O
. O

Patients O
( O
n O
= O
739 O
) O
with O
stage O
M1 O
( O
bone O
or O
soft O
tissue O
metastasis O
) O
prostate O
cancer O
were O
enrolled O
in O
a O
QOL O
protocol O
that O
was O
a O
companion O
to O
Southwest O
Oncology O
Group O
INT-0105 O
, O
a O
randomized O
double-blind O
trial O
comparing O
treatment O
with O
bilateral O
orchiectomy O
( O
surgical O
castration O
) O
plus O
either O
flutamide O
or O
placebo O
. O

This O
study O
was O
a O
pilot O
randomized O
controlled O
trial O
. O

Nine O
hundred O
and O
sixty-four O
patients O
were O
recruited O
from O
71 O
centers O
. O

Exclusion O
criteria O
included O
infectious O
conditions O
, O
intestinal O
obstruction O
, O
severe O
malnutrition O
, O
American O
Society O
of O
Anesthesiologists O
score O
C4 O
, O
intestinal O
resection O
, O
and O
postoperative O
stay O
in O
the O
intensive O
care O
unit O
lasting O
24 O
h. O
Patients O
allocated O
to O
EOF O
received O
liquid O
diet O
in O
the O
first O
postoperative O
day O
and O
then O
regular O
diet O
. O

Due O
to O
concerns O
of O
fragility O
fracture O
, O
exercise O
is O
a O
perceived O
contraindication O
for O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

This O
study O
is O
registered O
, O
ISRCTN87786644 O
. O

The O
impact O
of O
the O
addition O
of O
docetaxel O
on O
patients O
' O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
and O
symptoms O
was O
investigated O
. O

However O
, O
because O
of O
toxicity O
associated O
with O
long-term O
bisphosphonate O
treatment O
, O
establishing O
the O
lowest O
effective O
dose O
is O
important O
. O

The O
aim O
of O
this O
trial O
was O
to O
determine O
the O
value O
of O
thymidylate O
synthase O
( O
TS O
) O
, O
a O
key O
enzyme O
of O
DNA O
synthesis O
and O
target O
of O
5-FU O
, O
to O
predict O
response O
to O
chemotherapy O
of O
mCRC O
. O

Ongoing O
studies O
are O
exploring O
alternate O
schedules O
to O
maximize O
synergy O
between O
these O
agents O
. O

The O
DDI O
score O
was O
improved O
significantly O
in O
only O
the O
UAE O
group O
at O
6 O
months O
and O
afterward O
( O
P O
< O
.05 O
) O
. O

The O
primary O
end-point O
of O
the O
trial O
was O
length O
of O
hospital O
stay O
. O

The O
trial O
was O
stopped O
for O
futility O
at O
interim O
analysis O
. O

On O
November O
18 O
, O
2004 O
, O
the O
FDA O
granted O
erlotinib O
regular O
approval O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

We O
also O
evaluated O
the O
correlation O
between O
these O
scores O
and O
FACT-G O
, O
-B O
, O
and O
-Taxane O
scores O
at O
each O
time O
point O
. O

All O
patients O
were O
treated O
according O
to O
standard O
local O
practice O
. O

Patients O
aged O
18-75 O
years O
, O
undergoing O
an O
elective O
laparotomy O
and O
with O
a O
preoperative O
suspicion O
of O
gynecologic O
malignancy O
, O
were O
eligible O
. O

Of O
the O
120 O
participants O
randomly O
assigned O
, O
78 O
( O
65 O
% O
) O
completed O
the O
post-treatment O
assessment O
and O
67 O
( O
56 O
% O
) O
completed O
the O
2-month O
follow-up O
. O

One O
hundred O
patients O
with O
mild-moderate O
pain O
were O
randomized O
to O
treatment O
according O
to O
WHO O
guidelines O
or O
to O
treatment O
with O
strong O
opioids O
. O

Patients O
received O
either O
r-HuEPO O
( O
150 O
U/kg O
) O
or O
placebo O
, O
subcutaneously O
, O
three O
times O
a O
week O
for O
3 O
months O
. O

Significance O
was O
set O
at O
alpha O
< O
or O
= O
0.01 O
. O

Satisfaction O
was O
assessed O
with O
a O
seven-point O
Likert O
scale O
. O

This O
study O
addressed O
the O
effects O
of O
pilates O
exercise O
, O
as O
a O
new O
approach O
, O
on O
functional O
capacity O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
in O
whom O
there O
are O
doubts O
regarding O
the O
efficacy O
and O
usefulness O
of O
the O
exercise O
. O

Mean O
age O
was O
58 O
± O
10 O
years O
, O
57 O
% O
were O
female O
, O
and O
65 O
% O
were O
given O
palliative O
chemotherapy O
. O

We O
performed O
a O
4-arm O
randomised O
trial O
to O
compare O
( O
1 O
) O
a O
low-dose O
intravenous O
bolus O
of O
LV O
( O
20 O
mg/m2 O
) O
, O
followed O
by O
an O
intravenous O
bolus O
of O
5FU O
( O
400 O
mg/m2 O
) O
, O
followed O
by O
a O
22-hour O
continuous O
infusion O
of O
5FU O
( O
600 O
mg/m2 O
) O
on O
day O
1 O
and O
day O
2/2 O
weeks O
( O
ldLV5FU2 O
arm O
) O
, O
( O
2 O
) O
a O
weekly O
continuous O
infusion O
of O
high-dose O
5FU O
( O
2.6 O
g/m2/week O
) O
for O
6 O
weeks O
followed O
by O
a O
rest O
week O
( O
HD-FU O
arm O
) O
and O
( O
3 O
) O
raltitrexed O
( O
Tomudex O
arm O
";" O
3 O
mg/m2/3 O
weeks O
) O
to O
standard O
LV5FU2 O
. O

Five O
hundred O
seventy-three O
glioblastoma O
multiforme O
patients O
were O
randomized O
to O
receive O
either O
temozolomide O
+ O
radiotherapy O
( O
n O
= O
287 O
) O
or O
radiotherapy O
alone O
( O
n O
= O
286 O
) O
. O

Outcome O
measures O
were O
overall O
survival O
( O
OS O
) O
";" O
progression-free O
survival O
( O
PFS O
) O
";" O
-1 O
, O
-2 O
, O
and O
3-year O
survival O
rates O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
a O
novel O
mindfulness O
intervention O
called O
mindfulness-based O
art O
therapy O
( O
MBAT O
) O
versus O
standard O
educational O
support O
, O
on O
indices O
of O
stress O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
with O
high O
stress O
levels O
. O

The O
predefined O
primary O
criterion O
for O
successful O
ablation O
was O
" O
no O
visible O
uptake O
in O
the O
thyroid O
bed O
, O
or O
if O
visible O
, O
fractional O
uptake O
less O
than O
0.1 O
% O
" O
on O
neck O
scans O
performed O
8 O
months O
after O
therapy O
and O
was O
satisfied O
in O
100 O
% O
of O
patients O
in O
both O
groups O
. O

Discharged O
patients O
were O
followed-up O
in O
the O
outpatient O
clinic O
. O

We O
compared O
initial O
costs O
and O
costs O
during O
follow-up O
. O

Twenty-five O
of O
51 O
recruited O
patients O
completed O
therapy O
at O
the O
time O
of O
the O
planned O
interim O
analysis O
( O
median O
age O
, O
75 O
years O
";" O
range O
, O
70-82 O
) O
. O

A O
total O
of O
157 O
patients O
were O
randomized O
to O
UAE O
or O
surgery O
( O
hysterectomy O
or O
myomectomy O
) O
. O

Anaemia O
is O
common O
in O
patients O
receiving O
chemotherapy O
, O
causing O
symptoms O
that O
have O
a O
major O
impact O
on O
quality O
of O
life O
( O
QoL O
) O
. O

Ninety-seven O
patients O
being O
offered O
outpatient-based O
cancer O
treatment O
were O
randomised O
to O
treatment O
delivered O
in O
a O
hospital O
day O
unit O
, O
at O
the O
patient O
's O
home O
or O
in O
local O
general O
practice O
( O
GP O
) O
surgeries O
. O

A O
randomized O
phase O
III O
trial O
was O
conducted O
to O
determine O
whether O
combination O
therapy O
with O
13-cis-retinoic O
acid O
( O
13-CRA O
) O
plus O
interferon O
alfa-2a O
( O
IFNalpha2a O
) O
is O
superior O
to O
IFNalpha2a O
alone O
in O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O

A O
total O
of O
243 O
patients O
with O
stage O
II O
to O
IIIA/B O
non-small-cell O
lung O
cancer O
received O
induction O
paclitaxel O
225 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
days O
1 O
and O
22 O
and O
carboplatin O
area O
under O
the O
curve O
( O
AUC O
) O
days O
1 O
and O
22 O
, O
followed O
by O
concurrent O
weekly O
paclitaxel O
( O
50 O
mg/m O
( O
2 O
) O
IV O
) O
and O
carboplatin O
( O
AUC O
2 O
) O
, O
and O
hyperfractionated O
radiation O
therapy O
( O
69.6 O
Gy O
at O
1.2 O
Gy O
bid O
) O
. O

Normally O
distributed O
data O
were O
analyzed O
using O
t O
tests O
and O
random-slope/random-intercept O
mixed O
models O
. O

Patients O
( O
n O
= O
429 O
) O
were O
randomly O
assigned O
to O
receive O
doxorubicin O
50 O
mg/m O
( O
2 O
) O
plus O
docetaxel O
75 O
mg/m O
( O
2 O
) O
( O
n O
= O
214 O
) O
or O
doxorubicin O
60 O
mg/m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg/m O
( O
2 O
) O
( O
n O
= O
215 O
) O
on O
day O
1 O
, O
every O
3 O
weeks O
for O
up O
to O
eight O
cycles O
. O

Patients O
had O
a O
free O
choice O
of O
treosulfan O
i.v O
. O

Primary O
analyses O
were O
done O
by O
intention O
to O
treat O
and O
were O
based O
on O
scale O
scores O
at O
4 O
weeks O
and O
8 O
weeks O
. O

To O
determine O
the O
efficacy O
, O
impact O
on O
quality-of-life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

The O
median O
dose O
intensity O
delivered O
for O
C O
and O
E O
reached O
, O
respectively O
, O
85 O
% O
and O
87 O
% O
of O
that O
planned O
in O
the O
CEF O
arm O
and O
96 O
% O
and O
95 O
% O
of O
that O
planned O
in O
the O
EC O
arm O
. O

Consented O
participants O
were O
randomized O
to O
an O
experimental O
group O
( O
EG O
) O
( O
12 O
weekly O
MMP O
sessions O
) O
or O
a O
control O
group O
( O
no O
sessions O
) O
. O

This O
study O
examined O
( O
i O
) O
whether O
patient-caregiver O
dyads O
( O
i.e. O
, O
pairs O
) O
randomly O
assigned O
to O
a O
brief O
or O
extensive O
dyadic O
intervention O
( O
the O
FOCUS O
Program O
) O
had O
better O
outcomes O
than O
dyads O
randomly O
assigned O
to O
usual O
care O
and O
( O
ii O
) O
whether O
patients O
' O
risk O
for O
distress O
and O
other O
factors O
moderated O
the O
effect O
of O
the O
brief O
or O
extensive O
program O
on O
outcomes O
. O

The O
primary O
outcome O
assessed O
was O
progression-free O
survival O
( O
PFS O
) O
";" O
secondary O
outcomes O
included O
treatment-free O
survival O
( O
TFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
treatment-related O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
according O
to O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
's O
Quality O
of O
Life O
Questionnaire O
C-30 O
version O
1.0 O
instrument O
. O

We O
therefore O
investigated O
whether O
avoiding O
axillary O
surgery O
in O
older O
women O
would O
result O
in O
improved O
quality O
of O
life O
( O
QL O
) O
with O
similar O
disease-free O
survival O
( O
DFS O
) O
and O
overall O
survival O
( O
OS O
) O
. O

Thirty-nine O
patients O
were O
randomly O
assigned O
to O
CONNECT O
and O
36 O
to O
usual O
care O
. O

Nocturnal O
administration O
of O
branched-chain O
amino O
acid O
( O
BCAA O
) O
granules O
improves O
serum O
albumin O
levels O
in O
patients O
with O
cirrhosis O
. O

Using O
validated O
instruments O
, O
we O
prospectively O
assessed O
QOL O
( O
even O
after O
completion O
of O
protocol O
treatment O
) O
as O
one O
of O
the O
secondary O
end O
points O
of O
the O
V325 O
phase O
III O
trial O
. O

The O
setting O
was O
in O
a O
hydrotherapy O
pool O
, O
1.2 O
m O
depth O
, O
and O
a O
temperature O
of O
32-33 O
degrees O
capital O
ES O
, O
Cyrillic O
. O

Transthoracic O
and O
transhiatal O
esophagectomy O
are O
two O
common O
procedures O
for O
esophageal O
cancer O
resection O
. O

Safe O
resistance O
exercise O
prescription O
may O
counteract O
this O
effect O
. O

To O
carry O
out O
a O
preliminary O
trial O
evaluating O
the O
effectiveness O
of O
two O
types O
of O
homeopathy O
for O
the O
treatment O
of O
menopausal O
symptoms O
in O
breast O
cancer O
survivors O
. O

Premenopausal O
women O
with O
breast O
cancer O
receiving O
adjuvant O
chemotherapy O
are O
at O
risk O
for O
amenorrhea O
. O

The O
trial O
was O
designed O
to O
use O
one-sided O
tests O
of O
significance O
for O
power O
calculations O
, O
but O
is O
now O
reported O
with O
both O
one-sided O
and O
the O
traditional O
two-sided O
tests O
of O
significance O
. O

Women O
with O
a O
history O
of O
breast O
cancer O
who O
had O
completed O
all O
surgery O
, O
chemotherapy O
, O
and O
radiation O
treatment O
and O
who O
had O
an O
average O
of O
at O
least O
three O
hot O
flashes O
per O
day O
for O
the O
previous O
month O
. O

We O
aimed O
to O
determine O
the O
effect O
of O
dietary O
counseling O
or O
oral O
supplements O
on O
outcome O
for O
patients O
with O
cancer O
, O
specifically O
, O
nutritional O
outcome O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
, O
during O
and O
3 O
months O
after O
radiotherapy O
. O

The O
applicant O
has O
committed O
to O
conduct O
post-marketing O
clinical O
trials O
to O
assess O
further O
the O
effect O
of O
epidermal O
growth O
factor O
receptor O
expression O
, O
measured O
with O
immunohistochemical O
staining O
, O
on O
erlotinib O
treatment O
effect O
. O

We O
examined O
the O
efficacy O
and O
safety O
of O
adding O
gemcitabine O
to O
paclitaxel/bevacizumab O
( O
PB O
) O
. O

Older O
breast O
cancer O
survivors O
( O
BCSs O
) O
are O
at O
risk O
for O
late O
and O
long-term O
treatment O
effects O
on O
quality O
of O
life O
( O
QOL O
) O
, O
including O
lower O
physical O
functioning O
and O
fear O
of O
recurrence O
. O

The O
Wilcoxon O
rank O
sum O
test O
was O
used O
to O
compare O
summary O
scores O
between O
the O
two O
interventions O
. O

This O
randomised O
non-inferiority O
trial O
was O
designed O
to O
assess O
whether O
radiosurgery O
plus O
adjuvant O
whole O
brain O
radiotherapy O
( O
RS O
+ O
WBRT O
) O
is O
as O
effective O
as O
surgery O
plus O
whole O
brain O
radiotherapy O
( O
S O
+ O
WBRT O
) O
for O
cancer O
patients O
with O
a O
solitary O
brain O
metastasis O
, O
with O
respect O
to O
overall O
survival O
and O
quality O
of O
life O
. O

The O
Pain O
Education O
Program O
was O
tailored O
to O
the O
needs O
of O
the O
individual O
patient O
and O
consisted O
of O
three O
elements O
: O
( O
1 O
) O
educating O
patients O
about O
the O
basic O
principles O
regarding O
pain O
and O
pain O
management O
";" O
( O
2 O
) O
instructing O
patients O
how O
to O
report O
their O
pain O
in O
a O
pain O
diary O
";" O
and O
( O
3 O
) O
instructing O
patients O
how O
to O
communicate O
about O
pain O
and O
how O
to O
contact O
health O
care O
providers O
. O

Sensitivity O
analysis O
using O
pattern-mixture O
models O
determined O
the O
effect O
of O
study O
discontinuation O
on/before O
week O
24 O
. O

Analyses O
of O
covariance O
were O
used O
to O
study O
the O
long-term O
effectiveness O
of O
CBT O
. O

Caregivers O
and O
patients O
are O
adversely O
affected O
. O

This O
trial O
was O
undertaken O
to O
determine O
whether O
adjuvant O
treatment O
with O
the O
metalloproteinase O
inhibitor O
marimastat O
could O
prolong O
survival O
in O
responding O
patients O
with O
SCLC O
after O
chemotherapy O
. O

One O
hundred O
twenty-six O
patients O
referred O
for O
resection O
of O
the O
esophagus O
( O
n O
= O
48 O
) O
, O
stomach O
( O
n O
= O
28 O
) O
, O
or O
pancreas O
( O
n O
= O
50 O
) O
were O
considered O
to O
be O
included O
before O
operation O
. O

It O
is O
recommended O
to O
provide O
pain O
management O
education O
to O
all O
cancer O
patients O
. O

The O
AVEREL O
trial O
[ O
A O
Study O
of O
Avastin O
( O
Bevacizumab O
) O
in O
Combination O
With O
Herceptin O
( O
Trastuzumab O
) O
/Docetaxel O
in O
Patients O
With O
HER2-Positive O
Metastatic O
Breast O
Cancer O
] O
evaluated O
first-line O
bevacizumab-containing O
therapy O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
locally O
recurrent/metastatic O
breast O
cancer O
( O
LR/MBC O
) O
. O

HDCT O
was O
repeated O
after O
6 O
weeks O
. O

Observational O
studies O
demonstrate O
an O
association O
between O
physical O
activity O
and O
improved O
outcomes O
in O
breast O
and O
colon O
cancer O
survivors O
. O

Questionnaires O
were O
administered O
by O
a O
clinician O
blinded O
to O
treatment O
. O

Fortunately O
, O
cognitive-behavioral O
therapy O
for O
insomnia O
( O
CBT-I O
) O
has O
been O
shown O
to O
be O
an O
effective O
treatment O
in O
this O
population O
. O

After O
discharge O
, O
symptom O
severity O
, O
temperature O
, O
and O
medications O
used O
were O
recorded O
daily O
for O
1 O
week O
and O
symptom O
levels O
were O
measured O
for O
weeks O
2-4 O
. O

The O
experimental O
intervention O
consisted O
of O
reporting O
data O
from O
the O
standardized O
assessments O
to O
the O
IDTs O
. O

The O
intervention O
took O
place O
over O
a O
4-month O
period O
. O

One O
hundred O
fifty-nine O
patients O
with O
advanced O
colorectal O
carcinoma O
previously O
untreated O
for O
the O
metastatic O
disease O
( O
34 O
of O
them O
previously O
exposed O
to O
adjuvant O
5-FU O
) O
were O
randomly O
allocated O
to O
receive O
: O
CPT-11 O
, O
200 O
mg/m2 O
i.v O
. O

HRQOL O
was O
assessed O
at O
baseline O
, O
at O
end O
of O
cycle O
2 O
, O
and O
4 O
, O
6 O
, O
and O
9 O
months O
after O
completion O
of O
RT O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
QLQ O
Head O
and O
Neck O
Cancer-Specific O
Module O
( O
EORTC O
QLQ-H O
& O
amp O
";" O
N35 O
) O
. O

The O
regimens O
were O
compared O
with O
regard O
to O
effects O
on O
survival O
, O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

To O
investigate O
whether O
frequent O
hospital O
follow-up O
in O
the O
first O
year O
after O
breast O
cancer O
treatment O
might O
partly O
be O
replaced O
by O
nurse-led O
telephone O
follow-up O
without O
deteriorating O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
, O
and O
whether O
a O
short O
educational O
group O
programme O
( O
EGP O
) O
would O
enhance O
HRQoL O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Twenty-one O
centers O
in O
The O
Netherlands O
. O

Chronic O
gastrointestinal O
symptoms O
after O
pelvic O
radiotherapy O
are O
common O
, O
multifactorial O
in O
cause O
, O
and O
affect O
patients O
' O
quality O
of O
life O
. O

Treatment-related O
quality O
of O
life O
was O
assessed O
by O
the O
Breast O
Chemotherapy O
Questionnaire O
( O
BCQ O
) O
before O
, O
during O
, O
and O
4 O
months O
after O
treatment O
in O
163 O
patients O
. O

The O
proportions O
of O
patients O
with O
evaluable O
baseline O
EORTC O
QLQ-C30 O
and O
STO22 O
questionnaires O
were O
balanced O
( O
83 O
% O
in O
FLOT O
and O
89 O
% O
in O
FLO O
) O
. O

The O
dose O
was O
escalated O
every O
7 O
days O
from O
3 O
to O
9 O
MU O
( O
by O
increments O
of O
3 O
MU O
) O
, O
unless O
> O
/= O
grade O
2 O
toxicity O
occurred O
, O
in O
which O
case O
dose O
escalation O
was O
stopped O
. O

Eighty-one O
pamidronate O
patients O
and O
80 O
control O
patients O
were O
monitored O
for O
a O
median O
of O
18 O
and O
21 O
months O
, O
respectively O
, O
for O
events O
of O
skeletal O
morbidity O
and O
the O
radiologic O
course O
of O
metastatic O
bone O
disease O
. O

Neither O
demographic O
nor O
medical O
variables O
explained O
this O
association O
. O

The O
purpose O
of O
this O
blinded O
, O
randomized O
clinical O
trial O
was O
to O
compare O
two O
topical O
agents O
( O
Calendula O
Weleda O
cream O
vs. O
Essex O
cream O
) O
in O
reducing O
the O
risk O
of O
severe O
acute O
radiation O
skin O
reactions O
( O
ARSR O
) O
in O
relation O
to O
adjuvant O
radiotherapy O
( O
RT O
) O
for O
breast O
cancer O
. O

The O
effects O
, O
safety O
, O
and O
QoL O
were O
determined O
and O
analyzed O
. O

Outcomes O
were O
compared O
between O
groups O
using O
analysis O
of O
covariance O
adjusted O
for O
baseline O
values O
. O

Randomized O
controlled O
trial O
conducted O
from O
November O
2003 O
through O
May O
2008 O
of O
322 O
patients O
with O
advanced O
cancer O
in O
a O
rural O
, O
National O
Cancer O
Institute-designated O
comprehensive O
cancer O
center O
in O
New O
Hampshire O
and O
affiliated O
outreach O
clinics O
and O
a O
VA O
medical O
center O
in O
Vermont O
. O

Using O
hierarchical O
cluster O
analysis O
, O
3 O
mutually O
exclusive O
symptom O
groupings O
were O
identified O
in O
the O
cohort O
. O

Between-group O
differences O
in O
change O
from O
baseline O
were O
assessed O
using O
linear O
mixed O
models O
with O
selected O
covariates O
. O

Time O
to O
disease O
progression O
, O
response O
rate O
, O
adverse O
events O
, O
and O
QOL O
were O
secondary O
end O
points O
. O

The O
intervention O
was O
delivered O
on O
an O
individual O
basis O
on O
3 O
occasions O
over O
a O
period O
from O
9 O
weeks O
to O
12 O
weeks O
, O
and O
the O
objective O
of O
the O
intervention O
was O
to O
alter O
fatigue-related O
thoughts O
and O
behavior O
. O

Patients O
allocated O
to O
the O
control O
group O
received O
standard O
follow-up O
only O
. O

A O
total O
of O
473 O
patients O
( O
234 O
to O
Sx O
+ O
Ax O
, O
239 O
to O
Sx O
) O
were O
randomly O
assigned O
. O

Each B-Claim
of I-Claim
these I-Claim
regimens I-Claim
produced I-Claim
clinically I-Claim
significant I-Claim
responses I-Claim
, I-Claim
and O
the B-Claim
observed I-Claim
median I-Claim
survival I-Claim
( I-Claim
18.9 I-Claim
months I-Claim
for I-Claim
all I-Claim
71 I-Claim
patients I-Claim
) I-Claim
compares I-Claim
favorably I-Claim
with I-Claim
previously I-Claim
published I-Claim
results I-Claim
, I-Claim
especially I-Claim
in I-Claim
the I-Claim
community I-Claim
setting I-Claim
. I-Claim

Results B-Premise
of I-Premise
exploratory I-Premise
analyses I-Premise
suggested I-Premise
that I-Premise
the I-Premise
CST I-Premise
intervention I-Premise
was I-Premise
more I-Premise
beneficial I-Premise
to I-Premise
patients/caregivers I-Premise
with I-Premise
Stage I-Premise
II I-Premise
and I-Premise
III I-Premise
cancers I-Premise
, I-Premise
whereas O
the B-Premise
education/support I-Premise
intervention I-Premise
was I-Premise
more I-Premise
beneficial I-Premise
to I-Premise
patients/caregivers I-Premise
with I-Premise
Stage I-Premise
I I-Premise
cancer I-Premise
. I-Premise

In O
addition O
to O
known O
clinical O
factors O
, O
patient-assessed B-Claim
QL I-Claim
variables I-Claim
appear I-Claim
to I-Claim
be I-Claim
prognostic I-Claim
for I-Claim
survival I-Claim
and I-Claim
response I-Claim
to I-Claim
chemotherapy I-Claim
in I-Claim
women I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Moreover O
, O
a B-Premise
significant I-Premise
lower I-Premise
serum I-Premise
C-reactive I-Premise
protein I-Premise
level I-Premise
was I-Premise
detected I-Premise
in I-Premise
glutamine-enriched I-Premise
TPN I-Premise
compared I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
. I-Premise

Although O
the O
study O
was O
not O
designed O
or O
powered O
to O
evaluate O
survival O
, O
a B-Premise
survival I-Premise
trend I-Premise
was I-Premise
noted I-Premise
favouring I-Premise
epoetin-alfa I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
median I-Premise
survival I-Premise
17 I-Premise
vs I-Premise
11 I-Premise
months I-Premise
[ I-Premise
p I-Premise
= I-Premise
0.126 I-Premise
] I-Premise
) I-Premise
. I-Premise

The B-Premise
PFS I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
( I-Premise
6.2 I-Premise
vs. I-Premise
4.3 I-Premise
months I-Premise
, I-Premise
odds I-Premise
ratio I-Premise
0.66 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
, I-Premise
while O
the B-Premise
overall I-Premise
survival I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
14.8 I-Premise
months I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
vs. I-Premise
14.1 I-Premise
months I-Premise
in I-Premise
control I-Premise
arm I-Premise
) I-Premise
";" I-Premise
quality B-Claim
of I-Claim
life I-Claim
was I-Claim
similar I-Claim
as I-Claim
well I-Claim
. I-Claim

Thus O
, O
the B-Premise
rate I-Premise
of I-Premise
efficacy I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
( I-Premise
85.36 I-Premise
% I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
vs. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

